Overview
| 别名 | Fibroblast growth factor 23; FGF-23; Phosphatonin; Tumor-derived hypophosphatemia-inducing factor) [Cleaved into: Fibroblast growth factor 23 N-terminal peptide; Fibroblast growth factor 23 C-terminal peptide] |
| 基因名 | FGF23 |
| UniProt ID | Q9GZV9 |
| 反应种属 | Human |
| 应用 | WB |
| 宿主 | Mouse |
| 偶联物 | Unconjugated |
| 修饰 | Unmodified |
| 亚型 | IgG1 |
| 克隆号 | 4T3-B3-K8 |
| 克隆性 | Monoclonal Antibody |
| 分子量 | Calculated MW: 27 kDa |
| 纯化方式 | Affinity Purified |
| 产品形式 | Liquid |
| 推荐稀释比 | WB-1:1000 |
| 存储缓冲液 | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.09% sodium azide |
| 保存温度 | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| 背景信息 | Fibroblast growth factor 23 (FGF23) is a 32-kDa glycoprotein that functions as a critical endocrine regulator of phosphate and vitamin D metabolism. Primarily secreted by osteocytes and osteoblasts, FGF23 requires the alpha-Klotho co-receptor to bind and activate fibroblast growth factor receptors (FGFRs) with high affinity. Its primary mechanism involves inhibiting renal sodium-phosphate cotransporters NaPi2a and NaPi2c to increase urinary phosphate excretion, while simultaneously suppressing 1-alpha-hydroxylase to reduce circulating calcitriol levels. Additionally, it enhances calcium reabsorption in the distal tubule via the TRPV5 channel. The protein undergoes essential post-translational modifications, including O-glycosylation by GALNT3 for stability and phosphorylation by FAM20C to regulate its cleavage. Clinically, dysregulation of FGF23 is central to disorders of phosphate homeostasis, including autosomal dominant hypophosphatemic rickets, tumor-induced osteomalacia, and complications associated with chronic kidney disease. |
检测原理